[8-K] MILESTONE SCIENTIFIC INC. Reports Material Event

Rhea-AI Filing Summary

Milestone Scientific Inc. reported it received a NYSE American notice that it is not in compliance with continued listing standards under Sections 1003(a)(ii) and (iii). The company must submit a plan of compliance by November 7, 2025. If the plan is accepted, the listing can continue with periodic reviews.

The Exchange may initiate delisting procedures if the plan is not accepted, if progress is insufficient, or if the company fails to regain compliance by April 8, 2027. Management is pursuing options to address the deficiency and intends to submit a plan by the deadline.

Positive

• None.

Negative

• NYSE American noncompliance notice with plan due by Nov 7, 2025 and potential delisting risk if compliance is not achieved by Apr 8, 2027.

Insights

Exchange listing & compliance analyst

Noncompliance notice starts a formal plan-and-review timeline.

Milestone Scientific disclosed a NYSE American noncompliance notice tied to continued listing standards (Sections 1003(a)(ii) and (iii)). The company must provide a plan by November 7, 2025, after which the Exchange may allow continued listing with periodic reviews if the plan is accepted.

The outcome depends on Exchange acceptance and execution against the plan. The notice also sets a backstop: failure to regain compliance by April 8, 2027 or to make adequate progress can lead to delisting procedures.

Key milestones are the plan submission by November 7, 2025 and the compliance deadline on April 8, 2027. Actual impact will hinge on the plan’s acceptance and subsequent progress under Exchange oversight.

false 0000855683 0000855683 2025-10-08 2025-10-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2025

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-14053 (Commission File Number) 13-3545623 (IRS Employer Identification No.)

220 South Orange Avenue, Livingston Corporate Park Livingston, New Jersey
(Address of principal executive offices) 070340
(Zip Code)

Registrant’s telephone number, including area code (973) 535-2717

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On October 8, 2025, Milestone Scientific Inc. (“the Company”) received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the Company is not in compliance with the continued listing standards as outlined in Section(s) 1003(a)(ii), and (iii) of the NYSE American Company Guide (the “Company Guide”). To maintain its listing, the Company must submit a plan of compliance by November 7, 2025, outlining the actions it has taken or will take to regain compliance. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange. If the plan is not accepted or if it is accepted but the Company fails to comply with the continued listing standards by April 8, 2027, or if the Company does not make progress consistent with the plan, the Exchange will initiate delisting procedures as appropriate. The Company’s management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Milestone Scientific Inc.
Dated: October 14, 2025	By:	/s/ Eric Hines
		Eric Hines
		Chief Financial Officer

FAQ

What did Milestone Scientific (MLSS) disclose in the 8-K?

The company received a NYSE American notice that it is not in compliance with continued listing standards under Sections 1003(a)(ii) and (iii).

When is MLSS’s compliance plan due to NYSE American?

The plan of compliance is due by November 7, 2025.

What happens if the plan is accepted?

MLSS may continue its listing, subject to periodic reviews by the Exchange.

What could trigger delisting of MLSS?

If the plan is not accepted, if progress is insufficient, or if MLSS fails to regain compliance by April 8, 2027, the Exchange may initiate delisting procedures.

How is MLSS responding to the notice?

Management is pursuing options to address the deficiency and intends to submit a compliance plan by the deadline.

Which listing standards are referenced?

NYSE American Company Guide Sections 1003(a)(ii) and 1003(a)(iii).